4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reaffirmed at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating restated by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other brokerages have also recently commented on FDMT. The Goldman Sachs Group decreased their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Bank of America cut their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Chardan Capital cut their price target on 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Royal Bank of Canada cut their price objective on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.56.

4D Molecular Therapeutics Trading Up 3.2%

FDMT stock opened at $4.50 on Wednesday. The stock’s 50 day simple moving average is $3.41 and its 200 day simple moving average is $4.56. The stock has a market capitalization of $208.46 million, a PE ratio of -1.58 and a beta of 2.84. 4D Molecular Therapeutics has a 12-month low of $2.24 and a 12-month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, research analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. Y Intercept Hong Kong Ltd purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $41,000. AQR Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. KLP Kapitalforvaltning AS bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $48,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.